Publications

PubMed Logo Click here for a complete list of publications

 

Selected Peer-reviewed Publications

1. Xu C, Buczkowski KA, Zhang Y, Asahina H, Beauchamp EM, Terai H, Li YY, Meyerson M, Wong KK, Hammerman PS. NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy. Mol Cancer Ther. 2015, in press.

2. Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS.  Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells. Oncogene. 2015 Apr 23;34(17):2167-77.

3. Fillmore CF, Xu C, Desai PT, Rowbotham SP, Lin Y, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors. Nature. 2015 Apr 9;520(7546):239-42.

4. Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15;21(6):1447-56.

5. Seiwert TS, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker TP, Brown CD, Pugh TJ, Stojanov P, Cho J, Lawrence M, Getz G, Bragelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal LD, Blair EA, Stenson KM, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 1;21(3):632-41.

6. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinoma. Nature. 2015 Jan 29;517(7536):576-82. PS Hammerman project analysis group co-chair.

7. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis A, Ivanova E, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, XU AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Isaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS* and Kucherlapati R with the TCGA Network. Characterization of HPV and Host-Genome Interactions in Primary Head and Neck Cancers. PNAS. 2014 Oct 28;111(43):15544-9. *Co-senior author

8. Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu S, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JJ, Yun C, Hammerman PS*, Mohammadi M, Janne PA, Gray NS. Development of covalent inhibitors that can overcome resistance to first generation FGFR kinase inhibitors. PNAS. 2014 Nov 11;111(45):E4869-77. *Co-senior author

9. Tchaicha JH, Akbay EA, Altabef A, Mikse OR, Kikuchi E, Rhee K, Liao RG, Bronson RT, Sholl LM, Meyerson M, Hammerman PS*, Wong KK. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Research. 2014 July 17. *Co-senior author

10. Xu X, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, Herter-Sprie G, Akbay EA, Tchaicha JH, Altabef A, Reibel JB, Walton Z, Ji H, Watanabe H, Castrillion DH, Rustgi AK, Bass AJ, Freeman GJ, Padera RF, Janne PA, Dranoff G, Hammerman PS*, Kim CF, Wong KK. Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated Pdl1 Expression. Cancer Cell. 2014 May 12;25(5):590-604. *Co-senior author

11. Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. 2014 Feb;13(2):475-82.

12. Kim Y Hammerman PS*, Kim J, Yoon J, Lee Y, Sun J, Wilkerson MD, Pedamallu C, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh I, Kim HK, Choi YS, Kim K, Shim YM, Kim K, Song S, Na K, Choi Y, Hayes DN, Kim J, Cho S, Kim Y, Ahn JS, Ahn M, Getz G, Meyerson M, Park K. Integrative and comparative genomic analysis of East-Asian lung squamous cell carcinomas. J Clin Oncol. 2014 Jan 10;32(2):121-8. *Co-first authorship

13. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Butaney M, Cherniack AD, Beauchamp EM, Pugh TJ, Reibel JR, Cohoon TJ, Wilkerson MD, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Scholl LM, Rodig SJ, Freeman GJ, Hammerman PS*, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec;3(12):1355-63. *Co-senior author
   
14. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Donkin D, Giacomelli AO, Du C, Fries D, Wong KK, Mesirov JP, Leoffler JS, Schreiber SL, Hammerman PS*, Meyerson M. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013 Oct 15;73(20):6289-98. *Co-senior author

15. Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Liu Q, Pugh TJ, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013 Aug 15;73(16):5195-205

16. Cancer Genome Atlas Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. PS Hammerman writing committee and analysis group co-chair.

Address: 450 Brookline Avenue, Dana 810A, Boston, MA 02215
Telephone: 617-632-6335
FAX: 617-582-9830
E-mail: peter_hammerman@dfci.harvard.edu